AstraZeneca PLC (NYSE: AZN) disclosed Thursday that it is planning to supply 180 million COVID-19 vaccines to Europe in Q2. The firm will deliver 20 million to Italy. EU authorities have shown concerns about the supply of the vaccine.
Earlier, it had been revealed that AstraZeneca anticipated providing less than half the COVID-19 vaccines it was signed to provide the EU in Q2. CEO of AZN disclosed that the firm will provide nearly 5 million vaccine dosages by the end of March. This quantity is less than it has earlier signed for. By the end of June, the firm will deliver nearly 25 million doses to Italy.
EU lawmakers commented that it is difficult to get reliable data from AstraZeneca. The firm is behaving like a second-hand car salesman. The EU official discussed with the firm and commented that AstraZeneca had offered no data on which global locations it will provide the EU and whether trade restrictions and regulatory problems could hinder delivery.
EU is discussing with the firm to guarantee the deliveries of an adequate number of doses on time. If AstraZeneca will supply the 180 million dosages in Q2, it would still far behind the commitment it had made to supply 300 million dosages by the end of June. Shares of AstraZeneca went up 1.60% at $50.10 during the trading session of Wednesday. The firm has a total market capitalization of 134.24 billion at the time of writing.